Advances in therapeutic approaches to ulcerative colitis and Crohn's disease

Current Gastroenterology Reports

Volumn 7, Issue 6, 2005, Pages 475-484

  Travis, Simon ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ABT 874; ADALIMUMAB; ALICAFORSEN; AMINOSALICYLIC ACID; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CERTOLIZUMAB PEGOL; CORTICOSTEROID DERIVATIVE; FONTOLIZUMAB; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); IMMUNOMODULATING AGENT; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 12P40; INTERLEUKIN 6 ANTIBODY; MESALAZINE; METHOTREXATE; MONOCLONAL ANTIBODY; NATALIZUMAB; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLACEBO; PROBIOTIC AGENT; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; SEMAPIMOD; THALIDOMIDE DERIVATIVE; TREFOIL PEPTIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VISILIZUMAB;

ADOPTIVE IMMUNOTHERAPY; BONE PAIN; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST CONTROL; CROHN DISEASE; DRUG DELIVERY SYSTEM; DRUG FATALITY; DRUG MECHANISM; DRUG MONITORING; DRUG RECEPTOR BINDING; ENTERITIS; ENZYME INHIBITION; HEALTH CARE COST; HISTOPLASMOSIS; HUMAN; INFECTION; INJECTION SITE REACTION; LEUKOPOIESIS; LIVER TOXICITY; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR MECHANICS; NEUROPATHY; PNEUMONIA; RECTUM HEMORRHAGE; REMISSION; REVIEW; SPONTANEOUS ABORTION; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; TREATMENT PLANNING; TUBERCULOSIS; ULCERATIVE COLITIS;

COLITIS, ULCERATIVE; CROHN DISEASE; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PROBIOTICS; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 29444449342     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-005-0079-9     Document Type: Review

References (83)

1. Bebb JR, Scott BB: Systematic review: How effective are the usual treatments for ulcerative colitis? Aliment Pharmacol Ther 2004, 20:143-149.
2. Bebb JR, Scott BB: Systematic review: How effective are the usual treatments for Crohn's disease? Aliment Pharmacol Ther 2004, 20:151-159.
3. Hanauer SB, Stromberg U: Oral Pentasa in the treatment of active Crohn's disease: a meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol 2004, 2:379-388.
4. Feagan BG: 5-ASA therapy for active Crohn's disease: old friends, old data, and a new conclusion. Clin Gastroenterol Hepatol 2004, 2:376-378.
5. Hanauer SB: The case for using 5-aminosalicylates in Crohn's disease: pro. Inflamm Bowel Dis 2005, 11:609-612.
6. Hanauer SB, Sandborn WJ, Katz S, et al.: Efficacy and safety of mesalazine 4.8g/day (800mg tablet) compared with 2.4g/day (400mg tablet) in treating moderately active ulcerative colitis: ASCEND II study. Gut 2005, 54(Suppl II):A3.
7. Hanauer SB, Sandborn W, Kornbluth A, et al.: Delayed-release mesalamine 4.8g/day (800mg tablet) versus 2.4g/day (400mg tablet) for treatment of moderately active ulcerative colitis: combined analysis of two randomised, double-blind, controlled trials. Gastroenterology 2005, 128(Suppl 2):A-74.
8. Kane S, Huo D, Aikens J, Hanauer S: Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003, 114:39-43.
9. Marteau PR, Probert C, Lindgren S, et al.: Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active colitis: a randomised, double-blind, placebo controlled study. Gut 2005, 54:960-965.
10. Travis SPL: Transatlantic divide: first line therapy for acute colitis. Pract Gastroenterol 2005, 29:66-70.
11. Rousseaux C, Lefebvre B, Dubuquoy L, et al.: Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med 2005, 201:1205-1215.
12. Van Staa TP, Card TR, Leufkens HG, Logan RF: 5-aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut 2005 Jun 30, [Epub ahead of print].
13. Frieri G, Mariateresa P, Brigida G, et al.: Long-term oral plus topical mesalazine in frequently relapsing ulcerative colitis. Dig Liver Dis 2005, 37:92-96.
14. Prantera C, Viscido A, Biancone L, et al.: A new oral delivery system for 5-ASA: preliminary clinical findings for MMx. Inflamm Bowel Dis 2005, 11:421-427.
15. Lichtenstein GP, Cohen RD, Feagan BG, et al.: Safety of infliximab and other Crohn's disease therapies: updated Treat registry data with over 10 000 patient-years of follow-up. Gastroenterology 2005, 128(Suppl 2):A-580.
16. Creed TJ, Dayan CM, Probert CSJ, Hearing SD: Basiiximab for steroid-resistant ulcerative colitis. Gut 2004, 53(Suppl III):A97
17. Franchimont D: Overview of the actions of glucocorticoids on the immune response: a good model to characterize new pathways of immunosuppression for new treatment strategies. Ann N Y Acad Sci 2004, 1024:124-137.
18. Lowenberg M, Verhaar A, vand den Blink B, et al.: Essential role for c-Raf in steroid-insensitive Crohn's disease Gastroenterology 2005, 128(Suppl 2):A-505.
19. Tiede I, Fritz G, Strand S, et al.: CD28-dependent Rac 1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003, 111:1143-1145.
20. Aberra FN, Lichtenstein GR: Review article: Monitoring of immunomodulators in inflammatory bowel disease. Aliment Pharmacol Ther 2005, 21:307-319.
21. Neurath MF, Viesslich R, Tiechgräber U, et al.: Analysis of 6-thioguanosine di- (TGDP) and triphosphate (TGTP) levels as a novel method for clinical monitoring of azathioprine therapy in Crohn's disease. Gastroenterology 2005, 128(Suppl 2):A-12.
22. Hanauer SB, Korelitz BI, Rutgeerts P, et al.: Post-operative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine or placebo: a 2 year trial. Gastroenterology 2004, 127:723-729.
23. Ardizzone S, Maconi G, Sampietro GM, et al.: Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology 2004, 127:730-737.
24. Cosnes J, Nion-Larmurier I, Beaugere L, et al.: Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005, 54:237-241.
25. Dejaco C, Angelberger S, Waldhoer T et al.: Pregnancy and birth outcome under thiopurine therapy for inflammatory bowel disease. Gastroenterology 2005, 128(Suppl 2):A-12.
26. Siegel CA, Sands BE: Review article: Practical management of inflammatory bowel disease patients taking immunomodulators. Aliment Pharmacol Ther 2005, 22:1-16.
27. Cummings JRF, Herrlinger KR, Travis SP, et al.: Oral methotrexate in ulcerative colitis. Aliment Pharmacol Ther 2005, 21:385-389.
28. Van Assche G, D'Haens G, Noman M, et al.: Randomized, double-blind comparison of 4mg/kg versus 2mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003, 125:1025-1031.
29. Järnerot G, Hertervig E, Friis-Liby I, et al.: Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005, 128:1805-11.
30. Campbell S, Travis SPL, Jewell DP: Ciclosporin use in acute ulcerative colitis: a long-term experience. Eur J Gastroenterol Hepatol 2005, 17:79-84.
31. Baumgart DC, Pintoffl JP, Sturm A, et al.: Tacrolimus (FK506) rescue therapy is safe and effective in patients with severe and refractory inflammatory bowel disease: a long term follow up. Gastroenterology 2005, 128(Suppl 2):A-198.
32. Rutgeerts P, Feagan BG, Olson A, et al.: A randomised placebo-controlled trial of infliximab therapy for active ulcerative colitis: Act 1 trial. Gastroenterology 2005, 128(Suppl 2):A-105.
33. Sandborn WJ, Rachmilewitz D, Hanauer SB, P, et al.: Infliximab induction and maintenance therapy for active ulcerative colitis: the Act 2 trial. Gastroenterology 2005, 128(Suppl 2):A-104.
34. Targan SR, Hanauer SB, Van Deventer SJ, et al.: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997, 337:1029-1035.
35. Hommes DW, Baert F, Van Assche G, et al.: Management of recent onset Crohn's disease: a controlled randomized trial comparing step-up and top-down therapy. Gastroenterology 2005, in press.
36. Lémman M, Mary J-Y, Duclos B, et al.: Infliximab as a bridge therapy in steroid-dependent Crohn's disease patients treated with azathioprine. A randomized, double-blind, placebo-controlled trial. Gastroenterology 2005, in press.
37. Noman M, Vermeire S, Van Assche C, et al.: The effectiveness of immunosuppression to suppress formation of antibodies to infliximab in Crohn's disease. Gut 2004, 53 (Suppl VI):A-47.z
38. Ghosh S: Anti-TNF therapy in Crohn's disease. Novartis Found Symp 2004, 263:193-205, discussion 205-218.
39. Rampton DS: Preventing TB in patients with Crohn's disease needing infliximab or other anti-TNF therapy. Gut 2005, 54:1360-1362.
40. Shih CE, Bayless TM, Harris ML: Maintenance of longterm response to infliximab over 1 to 5 years in Crohn's disease including shortening doing intervals or increasing dosage. Gastroenterology 2004, 126(Suppl 2):A-631.
41. Williams JB, Cross RK, Thameen D, et al.: Long-term infliximab maintenance infusion regimens and rates of hospitalisation, surgery and disability in Crohn's disease patients. Gastroenterology 2005, 128(Suppl 2):A-589.
42. Rutgeerts P, Feagan BG, Lichtenstein GR, et al.: Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004, 126:402-413.
43. Lichtenstein GR, Yan S, Bala M, et al.: Infliximab maintenance treatment reduces hospitalizations, surgeries and procedures in fistulizing Crohn's disease. Gastroenterology 2005, 128:862-869.
44. Jewell DP, Satsangi J, Lobo A, et al.: Infliximab use in Crohn's disease: impact on health care resources in the UK. Eur J Gastroenterol Hepatol 2005, 17:1047-1052.
45. Nesbitt AM, Henry AJ: High affinity and potency of the pegylated FAB' fragment CDP870: a direct comparison with other anti-TNF agents. Gut 2004, 53(Suppl VI): A-47.
46. TM demonstrates significant positive results in its two pivotal phase III Crohn's disease trials. Internet press release 26 July 2005. Accessible at: http://ir.ucb-group.com/phoenix.zhtml?c=137495&p=irol- newsArticle&ID=735014&highlight=
47. MacIntosh DG, Lukas M, Sandborn W, et al.: A randomised, double-blind, placebo-controlled trial of the clinical assessment of adalimumab safety and efficacy studied as an induction therapy in Crohn's disease. Gut 2004, 53(Suppl VI):A-47.
48. Sandborn W, Hanauer S, Lukas M, et al.: Induction and maintenance of clinical remission and response in subjects with Crohn's disease treated during a 6-month open-label period with fully human anti-TNF alpha monoclonal antibody adalimumab (Humira). Gastroenterology 2005, 128(Suppl 2):A-111.
49. Papadakis KA, Shaye OA, Vasiliauskas EA, et al.: Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximah. Am J Gastroenterol 2005, 100:75-79.
50. Rutgeerts P, Reinisch W, Colombel J-F, et al.: Preliminary results of a phase I/II study of HuZAF an anti-IFNg monoclonal antibody in patients with moderate to severe active Crohn's disease. Gastroenterology 2002, 122 Suppl 4:A-61.
51. Van Assche G, Pearce T. Fontolizumab (Huzaf), a humanized anti-IFN-gamma antibody, has clinical activity and excellent tolerability in moderate to severe Crohn's disease. Gut 2004, 53(Suppl VI):A48.
52. De Villiers W, Katz S, Salzberg BA, et al.: Chronic dosing of fontolizumab (Huzaf), a humanised anti-IFN-gamma antibody in patients with moderate to severe Crohn's disease. Gastroenterology 2005, 128(Suppl 2):A-111.
53. Targan SR, Salzberg BA, Mayer L, et al.: A phase I-II study. multiple dose levels of visilizumab are well tolerated and produce rapid and sustained improvement in ulcerative colitis patients refractory to treatment with intravenous steroids (IVSR-UC). Gastroenterology 2005, 128(Suppl 2):A-75.
54. Hommes DW, Plevy S, Salzberg BA, et al.: Epstein-Barr virus (EBV) replication in severe active, steroid-resistant ulcerative colitis patients treated with visilizumab, an anti-CD3 antibody. Gastroenterology 2005, 128(Suppl 2):A-75.
55. Mannon PJ, Fuss I, Mayer L, et al.: Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 2004, 351:2069-2079.
56. Ito H, Takazoe M, Fukuda Y, et al.: A pilot randomised trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 2004, 126:989-996.
57. Feagan BG, Greenberg GR, Wild G, et al.: Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005, 352:2499-2507.
58. Rutgeerts P, Enns R, Colombel JF, et al.: 6-month steroid-sparing results of natalizumab in a controlled study of patients with Crohn's disease. Gut 2004, 53 (Suppl VI):A-48.
59. Van Assche G, Van Ranst M, Sciot R, et al.: Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005, 353:362-368.
60. Chey WY, Volfova M, Konecny M, et al.: Two phase 3 studies of alicaforsen (ISIS2302), an anti-sense oligonulceotide to human ICAM-1, in the treatment of moderate to severe Crohn's disease. Gastroenterology 2005, 128(Suppl 2):A-112.
61. Van Deventer SJ, Volfova M, Flisiak R, et al.: A phase 2 dose-ranging, double blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis. Gastroenterology 2005, 128(Suppl 2):A-74.
62. Miner PB, Nichols T, Schwartz H, et al.: A phase 2 trial to assess the safety and efficacy of two dose formulations of alicaforsen enema compared with mesalamine enema for acute ulcerative colitis. Gastroenterology 2005, 128(Suppl 2):A-74.
63. Braat H, Rottiers; P, Huyghebaert N, et al.: Interleukin-10 producing Lactococcus lactis for the treatment of Crohn's disease. Gastroenterology 2005, 128(Suppl 2):A-104.
64. Herrlinger KR, Witthoeft T, Raedler A, et al.: Randomised, double-blind, double-dummy, controlled trial of subcutaneous recombinant human interleukin-11 vs prednisolone in active Crohn's disease. Gut 2004, 53 (Suppl VI):A-49.
65. Mahmood A, Melley L, Fitzgerald A, et al.: Phase I/II trial of trefoil factor family 3 (TFF-3) enema therapy with oral mesalazine for mild to moderate left-sided colitis. Gastroenterology 2005, 128(Suppl 2):A-581.
66. Korzenik JR, Dieckgraefe B, Valentine IF, et al.: Sargramostim for active Crohn's disease. N Engl J Med 2005, 352:2193-2201.
67. Valentine J, Stone C, Korzenik J, et al.: Repeated cycles of sargramostim for active Crohn's disease: update from an open label trial (n.o.v.e.l. 5). Gastroenterology 2005, 128(Suppl 2):A-111.
68. Buchman AL, Katz S, Barish C, et al.: Semapimod treatment of Crohn's disease. Gastroenterology 2004, 126 Suppl 2:A-464.
69. Travis SPL, Yap LM, Hawkey CJ, et al.: RDP58 - a novel and potentially effective oral therapy for ulcerative colitis (UC): results of parallel prospective, multicenter, blinded, placebo-controlled trials. Inflamm Bowel Dis 2005, in press.
70. Hanauer SB, Miner PB, Keshavarzian A, et al.: Randomized, double-blind, placebo-controlled, parallel-arm, safety and efficacy trial of once-daily, oral OPC-6535 in the treatment of active ulcerative colitis. Gastroenterology 2004, 126 Suppl 2:A-112.
71. Schreiber SW, Forbes A, Feagan BG, et al.: Randomized, multicentre, double blind, placebo-controlled trial of once daily, oral OPC-6535 in the treatment of active ulcerative colitis: use of the disease activity index (DAI) to define study population and treatment response. Gut 2004, 53(Suppl VI):A-225.
72. Rieder F, Siegmund B, Lehr HA, et al.: The novel specific type-4 phosphodiesterase inhibitor roflumilast mitigates experimental colitis in mice. Gastroenterology 2005, 128(Suppl 2):A-203.
73. Summers RW, Elliott DE, Urban JF Jr, et al.: Trichuris suis therapy in Crohn's disease. Gut 2005, 54:87-90.
74. Summers RW, Elliott DE, Urban JF Jr, et al.: Trichuris suis therapy for active ulcerative colitis: a randomised controlled trial. Gastroenterology 2005, 128:825-32.
75. O'Neil J, Speare R, Melrose W, et al.: A pilot study establishing Necator americanus in Crohn's disease patients and normal controls. Gastroenterology 2005, 128: abstract.
76. Irving PM, Rampton DS: Leucocytapheresis for ulcerative colitis. Dig Liver Dis 2004, 36:799-802.
77. Barkholt L, Lofberg R: Resetting the immune system in refractory Crohn's disease: autologous haemopoetic stem cell transplantation the way forward? Gastroenterology 2005, 128:786-789.
78. Shanahan F: Physiological basis for novel drug therapies used to treat inflammatory bowel diseases I. Pathophysiological basis and prospects for probiotic therapy in inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2005, 288:G417-G421.
79. Cummings JH, Kong SC: Probiotics, prebiotics and antibiotics in inflammatory bowel disease. Novartis Found Symp 2004, 11:75-90.
80. Gionchetti P, Lammers KM, Rizzello F, Campieri M: Probiotics and barrier function in colitis. Gut 2005, 54:898-900.
81. Stremmel W, Merle U, Zahn A, et al.: Retarded release phosphatidyl choline benefits patients with chronic active ulcerative colitis. Gut 2005, 54:966-971.
82. Su C, Lichtenstein GR, Krok K, et al.: A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease. Gastroenterology 2004, 126:1257-1269.
83. Su C, Lewis JD, Goldberg B, et al.: Factors that influence placebo remission rates in clinical trials of active ulcerative colitis: a meta-analysis. Gastroenterology 2005, 128(Suppl 2):A-326.